Third Party Anti-Viral Cytotoxic T-Cells

2015-08-26 21:42:46 | BioPortfolio

Published on BioPortfolio: 2015-08-26T21:42:46-0400

Clinical Trials [2411 Associated Clinical Trials listed on BioPortfolio]

Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?

The working hypothesis is that the low HDL serum level predict favorable response to anti viral treatment in chronic HCV (genotype 1) viral infection. This might be used to improve the rat...

Donor-Derived Viral Specific T-cells (VSTs) for Prophylaxis Against Viral Infections After Allogeneic Stem Cell Transplant

The purpose of this research study is to learn more about the use of viral specific T-lymphocytes (VSTs) to prevent viral infections that may happen after allogeneic stem cell transplant. ...

Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients

The purpose of this study is to assess the duration of the viral shedding in hematology and oncology patients after a respiratory tract viral infection. This duration has not been much stu...

Impact of CMV Status on HIV Viral Load Decay

Background: Cytomegalovirus (CMV) infection is usually observed among patients with HIV infection. No study to date has investigated the impact of CMV infection on HIV viral load decay dur...

Respiratory Viral Infections in Pediatric Transplantation

A retrospective cohort of solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients will be assembled to determine the incidence of respiratory viral infections...

PubMed Articles [14512 Associated PubMed Articles listed on BioPortfolio]

Strength in Numbers: Mechanisms of Viral Co-infection.

RNA virus populations are diverse due to a variety of factors, including lack of proofreading of the viral RNA-dependent RNA polymerase. These diverse viral populations include defective viruses incap...

HDV evolution-will viral resistance be an issue in HDV infection?

Hepatitis D virus (HDV) is a hepatotropic subviral infectious agent, obligate satellite of the Hepatitis B virus (HBV) and is highly related to viroids. HDV affects around 5% of the 257 million chroni...

Adjuvant Haploidentical Virus-specific T Lymphocytes (VSTs) for Treatment of Disseminated Adenovirus Infection in a Premature Infant.

We report the first therapeutic infusion of haploidentical virus-specific T lymphocytes (VSTs) to treat maternally-transmitted, disseminated adenovirus infection in a premature infant. Infusion of mat...

ATRX promotes maintenance of herpes simplex virus heterochromatin during chromatin stress.

The mechanisms by which mammalian cells recognize and epigenetically restrict viral DNA are not well defined. We used herpes simplex virus with bioorthogonally labeled genomes to detect host factors r...

The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis.

European treatment guidelines for hepatitis C virus (HCV) infection recommend that people with genotype (GT)1a infection and baseline viral load ≤800,000 IU/mL receive elbasvir/grazoprevir (EBR/GZR)...

Medical and Biotech [MESH] Definitions

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.

INFLAMMATION of the LIVER in animals due to viral infection.

Inflammation of the lung parenchyma that is caused by a viral infection.

Inflammation, often mild, of the conjunctiva caused by a variety of viral agents. Conjunctival involvement may be part of a systemic infection.

Proteins associated with the inner surface of the lipid bilayer of the viral envelope. These proteins have been implicated in control of viral transcription and may possibly serve as the "glue" that binds the nucleocapsid to the appropriate membrane site during viral budding from the host cell.

More From BioPortfolio on "Third Party Anti-Viral Cytotoxic T-Cells"

Quick Search


Searches Linking to this Trial